RayKnowChina Research Map
Shortlist0

BeijingCapital Medical University

Beijing Chao-Yang Hospital

首都医科大学附属北京朝阳医院

Listed for 21 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Beijing Chao-Yang Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led
  2. Hepatocellular carcinoma肝细胞癌18 papers led
  3. Stomach cancer胃癌12 papers led
  4. Chordoma脊索瘤2 papers led
  5. Osteosarcoma骨肉瘤6 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Ewing sarcoma尤文肉瘤2 papers led
  9. Multiple myeloma多发性骨髓瘤52 papers led
  10. Beta thalassaemiaβ 地中海贫血0 papers led
  11. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
  12. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  13. Takayasu arteritis大动脉炎3 papers led
  14. Idiopathic pulmonary fibrosis特发性肺纤维化12 papers led
  15. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  16. Behçet disease白塞病1 paper led
  17. IgA nephropathyIgA 肾病4 papers led
  18. Primary biliary cholangitis原发性胆汁性胆管炎3 papers led
  19. Primary sclerosing cholangitis原发性硬化性胆管炎2 papers led
  20. Congenital diaphragmatic hernia先天性膈疝1 paper led
  21. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 3320242025: 112025

13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyMolecular markers & genomics
Departments in papersPathology / laboratory medicineMedical oncology
Papers it led8
  1. p53 and Ki-67 combined with periodic acid-Schiff staining for the diagnosis of early stage esophageal squamous cell carcinoma lesions in biopsy specimens.2025Esophagus : official journal of the Japan Esophageal SocietyFree full text
  2. Phospholipase PLCE1 Promotes Transcription and Phosphorylation of MCM7 to Drive Tumor Progression in Esophageal Cancer.2024Cancer research
  3. Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma.2024Journal of clinical pathology
  4. Correlation of PD-L1 expression with CD8+ T cells and oxidative stress-related molecules NRF2 and NQO1 in esophageal squamous cell carcinoma.2024The journal of pathology. Clinical researchFree full text
  5. Preventive Treatment with PD-1 Antibody Increases Tissue-resident Memory T Cells Infiltration and Delays Esophageal Carcinogenesis.2023Cancer prevention research (Philadelphia, Pa.)Free full text
  6. APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis.2023Pathology oncology research : PORFree full text
  7. High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients.2022Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  8. DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway.2021Molecular cancer research : MCR
More papers found outside PubMed (not counted)12
  1. 193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma2024Annals of Oncologyarticle
  2. Data from DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway2023Venue not listedother
  3. Supplementary Figure 4 from DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway2023Venue not listedsupplementary-materials
  4. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  5. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  6. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  7. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  8. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  9. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  10. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  11. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figsharedataset
  12. Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 18 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
18
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 5520232024: 4420242025: 112025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisSurgery & liver transplantLocal treatment (ablation, TACE, HAIC)
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led18
  1. Integrated analysis and experimental validation reveal the prognostic and immunological features associated with coagulation in hepatocellular carcinoma.2025Scientific reportsFree full text
  2. LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy.2024Cell death & diseaseFree full text
  3. Impact of metabolic dysfunction-associated fatty liver disease on liver transplant recipients with hepatitis B virus-related hepatocellular carcinoma.2024European journal of clinical nutrition
  4. Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma.2024Frontiers in endocrinologyFree full text
  5. Anti-PD-1 therapy reverses TIGIT+CD226+NK depletion in immunotherapy resistance of hepatocellular carcinoma through PVR/TIGIT pathway.2024International immunopharmacology
  6. Metformin promotes the normalization of abnormal blood vessels after radiofrequency ablation deficiency in hepatocellular carcinoma by microRNA-302b-3p targeting thioredoxin-interacting protein.2023Acta biochimica Polonica
  7. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.2023Cancer biology & medicineFree full text
  8. Therapeutically targeting essential metabolites to improve immunometabolism manipulation after liver transplantation for hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  9. Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.2023Frontiers in immunologyFree full text
  10. Unveiling the Mystery of SUMO-activating enzyme subunit 1: A Groundbreaking Biomarker in the Early Detection and Advancement of Hepatocellular Carcinoma.2023Transplantation proceedings
  11. Prognosis of Liver Transplantation for Hepatocellular Carcinoma in Terms of Different Criteria: A Single Center Experience.2022Current medical science
  12. Anatomic resection versus radiofrequency ablation with an ablative margin ≥ 1.0 cm for solitary small hepatocellular carcinoma measuring ≤ 3 cm: Comparison of long-term outcomes using propensity score matching analysis.2022European journal of radiology
  13. Safety and efficacy of microwave versus radiofrequency ablation for large hepatic hemangioma: a multicenter retrospective study with propensity score matching.2022European radiology
  14. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  15. Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.2022World journal of gastroenterologyFree full text
  16. Intrahepatic hemorrhage and recurrence caused by arterioportal fistula after radiofrequency ablation for hepatocellular carcinoma: A thought-provoking ablation-related complication.2021Asian journal of surgery
  17. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.2021MedicineFree full text
  18. PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma.2021Technology in cancer research & treatmentFree full text
Chinese-language papers (not in the count)1
  1. [Angio-associated migratory cell protein is highly expressed in hepatocellular carcinoma and promotes tumor cell invasion and metastasis].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular CarcinomaCompletedNCT00300521Lead sponsorPhase 2Start 2000-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 12 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 1120232024: 4420242025: 222025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNutrition & recoveryPeritoneal spread & advanced diseaseImaging & AI
Departments in papersPathology / laboratory medicineGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led12
  1. Lipidomic machine learning predictor for progression of gastric cancer.2026Clinica chimica acta; international journal of clinical chemistry
  2. Clinicopathological features and mucin expression of early papillary gastric adenocarcinoma.2025Scientific reportsFree full text
  3. Diagnostic Value of Joint Detection of Serum TK1, TSGF, CA199, and CA724 for Gastric Cancer and Its Relationship With Clinicopathologic Features and Prognosis.2025The American surgeon
  4. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.2024Cancer immunology, immunotherapy : CIIFree full text
  5. Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Gene Analysis.2024Critical reviews in immunology
  6. Advanced Gastric Cancer: CT Radiomics Prediction of Lymph Modes Metastasis After Neoadjuvant Chemotherapy.2024Journal of imaging informatics in medicineFree full text
  7. DNA methylation profiling identifies epigenetic signatures of early gastric cancer.2024Virchows Archiv : an international journal of pathology
  8. Multimodality Therapy, Followed by Laparoscopic Gastrectomy, for Unresectable Gastric Cancer With Outlet Obstruction and Bulky N2 Metastases.2023Surgical laparoscopy, endoscopy & percutaneous techniques
  9. Clinicopathological and molecular characteristics of the alpha-fetoprotein-producing gastric cancer: emphasis on two major subtypes.2022APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  10. Deep learning for automatic diagnosis of gastric dysplasia using whole-slide histopathology images in endoscopic specimens.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  11. Silencing of ER-resident oxidoreductase PDIA3 inhibits malignant biological behaviors of multidrug-resistant gastric cancer.2021Acta biochimica et biophysica Sinica
  12. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Chinese-language papers (not in the count)6
  1. [Neuroendocrine carcinoma with significantly vacuolar nucleus at the esophagogastric junction: A case report].2025Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
  2. [Clinicopathological features of Helicobacter pylori-negative early gastric cancer].2023Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
  3. [The value of Alcian blue periodic acid Schiff staining and Ki-67 expression in diagnosing gastric reactive epithelial hyperplasia and dysplasia].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Clinicopathological features of early gastric cancer after Helicobacter pylori eradication].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Clinicopathological features of very well-differentiated adenocarcinoma of the stomach].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  6. [Application and Progress of Convolutional Neural Network-based Pathological Diagnosis of Gastric Cancer].2021Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science editionFree full text
All its trials on ClinicalTrials.gov, any status5
  1. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  2. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  3. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  4. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  5. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 2 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

11 hospitals in Beijing for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 112025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 52 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 3.1%.

Papers led
52
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
14
led by another institution
Papers led per year
2021: 111120212022: 7720222023: 9920232024: 171720242025: 772025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 14

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  3. Recruiting
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07529782

    Age Not stated to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin

  4. Recruiting
    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07620275

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General Hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  5. Recruiting
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07297329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  6. Recruiting
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06375044

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou

  7. Recruiting
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06508983

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou

  8. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  9. Recruiting
    Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05565807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou

  10. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  11. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  12. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  13. Not yet recruiting
    Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2027-12
    Registry
    NCT07695740

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  14. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsStem cell transplant
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineMedical oncology
Papers it led52
  1. Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents.2026Transplantation and cellular therapy
  2. The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.2025Annals of hematology
  3. Temporal trends and disparities in cardiovascular disease-related mortality among adults with multiple myeloma in the United States, 1999-2023.2025BMC cardiovascular disordersFree full text
  4. Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients.2025BMC immunologyFree full text
  5. Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi-Center, Open-Label Phase I Trial.2025Cancer medicineFree full text
  6. Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study.2025Hematology (Amsterdam, Netherlands)
  7. Exploring multiple myeloma pathobiology and immune cell signatures: Evidence from bidirectional genetic analysis.2025MedicineFree full text
  8. Analysis of clinical characteristics, treatment response, and prognosis among 67 patients with anaplastic multiple myeloma.2025World journal of surgical oncologyFree full text
  9. Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.2024Annals of hematology
  10. Prognostic value of 18F-FDG PET/CT in patients with relapsed multiple myeloma.2024Annals of hematology
  11. Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.2024Annals of hematologyFree full text
  12. Myeloma extracellular vesicle-derived RAGE increases inflammatory responses and myotube atrophy in multiple myeloma through activation of the TLR4/NF-κB p65 pathway.2024Apoptosis : an international journal on programmed cell death
  13. Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients.2024Cancer medicineFree full text
  14. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.2024Cancer medicineFree full text
  15. KIAA1429 increases FOXM1 expression through YTHDF1-mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma.2024Cell biology and toxicologyFree full text
  16. Detection of lenalidomide metabolites in urine to discover drug-resistant compounds.2024Clinica chimica acta; international journal of clinical chemistry
  17. Proteomics analysis of serum and urine identifies VCP and CTSA as potential biomarkers associated with multiple myeloma.2024Clinica chimica acta; international journal of clinical chemistry
  18. Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors.2024Diagnostic pathologyFree full text
  19. Analysis of the efficacy of separation surgery for severe neurological compression in multiple myeloma: a retrospective analysis of 35 cases.2024European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  20. Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.2024Frontiers in immunologyFree full text
  21. Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center.2024Hematology (Amsterdam, Netherlands)
  22. Synchronous multiple myeloma and lung adenocarcinoma: A clinical series.2024Indian journal of pathology & microbiology
  23. Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.2024Journal of clinical laboratory analysisFree full text
  24. Wound healing after surgical therapy for multiple myeloma: a case-control study.2024Journal of wound care
  25. Which factors are associated with adverse prognosis in multiple myeloma patients after surgery? - preliminary establishment and validation of the nomogram.2024World journal of surgical oncologyFree full text
  26. The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma.2023Advances in therapyFree full text
  27. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.2023BMC cancerRCTFree full text
  28. Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.2023Blood advancesFree full text
  29. Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.2023Cancer medicineFree full text
  30. Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients.2023Clinical and experimental medicine
  31. In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model.2023Clinical and experimental medicine
  32. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.2023Hematology (Amsterdam, Netherlands)
  33. Biological research on the occurrence and development of multiple myeloma and its treatment.2023Immunity, inflammation and diseaseFree full text
  34. The effects of nutritional support on cellular immunity of the patient with multiple myeloma undergoing chemotherapy.2023Panminerva medica
  35. Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.2022Advances in therapy
  36. Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.2022BMC cancerFree full text
  37. Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China.2022Cancer epidemiology
  38. Echocardiography-defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients.2022Cancer medicineFree full text
  39. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.2022Cancer medicineFree full text
  40. Routine blood biomarkers for the detection of multiple myeloma using machine learning.2022International journal of laboratory hematology
  41. The Association Between Low T3 Syndrome and Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study.2022Technology in cancer research & treatmentFree full text
  42. Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.2021Annals of hematology
  43. The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.2021BioMed research internationalFree full text
  44. Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study.2021Chinese medical journalFree full text
  45. Promoting effects of MiR-135b on human multiple myeloma cells via regulation of the Wnt/β-catenin/Versican signaling pathway.2021Cytokine
  46. The Prevalence of Euthyroid Hypertriiodothyroninemia in Newly Diagnosed Multiple Myeloma and its Clinical Characteristics.2021Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  47. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.2021International journal of hematology
  48. Deep Learning-Based CT Imaging in Diagnosing Myeloma and Its Prognosis Evaluation.2021Journal of healthcare engineeringFree full text
  49. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.2021Leukemia & lymphoma
  50. Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.2021Leukemia & lymphoma
  51. LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN.2021Neoplasma
  52. Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma.2021Turkish journal of haematology : official journal of Turkish Society of HaematologyFree full text
Chinese-language papers (not in the count)20
  1. [The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].2025Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Analysis of Listeriosis in Treatment of Multiple Myeloma with Novel Agents].2025Zhongguo shi yan xue ye xue za zhi
  3. [Analysis of the efficacy of a carfilzomib-based regimen in the treatment of relapsed and refractory multiple myeloma].2025Zhonghua nei ke za zhi
  4. [Advances for treatment of relapsed or refractory multiple myeloma: interpretation of guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  5. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].2024Zhonghua nei ke za zhi
  6. [Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  7. [Analysis of the prognostic factors in primary plasma cell leukemia in the era of novel agents].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  8. [Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in the mobilization of autologous peripheral blood stem cells in patients with multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  9. [Minimal residual disease assessment and progress in multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  10. [MiR-203a-5p Inhibits Multiple Myeloma Cell Proliferation and Cell Cycle Progression via Targeting JAG1].2023Zhongguo shi yan xue ye xue za zhi
  11. [Application and significance of peripheral blood circulating plasma cells in the diagnosis of multiple myeloma].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  12. [Prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients who achieved deep response].2022Zhonghua nei ke za zhi
  13. [Interpretation of treatment of relapsed/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China(2022 revision)].2022Zhonghua nei ke za zhi
  14. [The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma].2022Zhonghua nei ke za zhi
  15. [Clinical analysis of 25 patients with non transplanted multiple myeloma who survived for more than 10 years].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  16. [MAS-like lesions and SIADH caused by bortezomib in the treatment of multiple myeloma : three cases report and literature review].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  17. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].2022Zhonghua yi xue za zhi
  18. [Controversies on the diagnosis and treatment of relapsed/refractory multiple myeloma].2022Zhonghua yi xue za zhi
  19. [Clinical Analysis of 25 Non-Transplanted Multiple Myeloma Patients Treated with Bortezomib Maintenance].2021Zhongguo shi yan xue ye xue za zhi
  20. [Autologous stem cell transplantation improve the survival of newly diagnosed multiple myeloma patients].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status45
  1. Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omicsStatus unknownNCT04678089Lead sponsorStart 2019-05
  2. CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary PlasmacytomaStatus unknownNCT02336386Lead sponsorPhase 3Start 2014-12
  3. Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma PatientsStatus unknownNCT02981199Lead (inferred)N/AStart 2016-01
  4. Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM PatientsStatus unknownNCT02572596Lead (inferred)N/AStart 2013-01
  5. Study of YKST02 in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07695740Study sitePhase 2Start 2027-12
  6. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  7. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Study sitePhase 1Start 2026-03
  8. Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMARecruitingNCT07620275Study sitePhase 1Start 2026-09
  9. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  10. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  11. A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07297329Study sitePhase 3Start 2025-12
  12. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Study sitePhase 1Start 2024-05
  13. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Study sitePhase 3Start 2024-06
  14. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06
  15. Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaRecruitingNCT05565807Study sitePhase 1/Phase 2Start 2023-02
  16. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  17. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  18. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  19. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT07266441Study sitePhase 2Start 2026-02
  20. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  21. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  22. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  23. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  24. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  25. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  26. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  27. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesActive, not recruitingNCT04684108Study sitePhase 1Start 2021-11
  28. A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190Study siteStart 2021-10
  29. A Study of TQB3820 in Patients With Hematological MalignanciesStatus unknownNCT05020639Study sitePhase 1Start 2021-08
  30. Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaStatus unknownNCT04818372Study sitePhase 1Start 2021-04
  31. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  32. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Study sitePhase 1/Phase 2Start 2021-04
  33. Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MMStatus unknownNCT05052970Study sitePhase 1Start 2021-10
  34. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  35. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  36. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  37. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  38. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  39. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  40. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  41. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  42. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  43. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  44. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Study sitePhase 3Start 2015-04
  45. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Detection of three common mutations causing β-thalassemia by using a closed-tube multiplex PCR.2018Experimental and molecular pathology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Beijing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 3 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineRheumatology & immunology
Papers it led3
  1. Predictors for pulmonary artery involvement in Takayasu arteritis and its cluster analysis.2023Arthritis research & therapy
  2. Analysis of clinical features between active and inactive patients of Takayasu's arteritis with pulmonary arteries involvement.2023International journal of cardiology
  3. Value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of pulmonary artery activity in patients with Takayasu's arteritis.2021European heart journal. Cardiovascular Imaging
Chinese-language papers (not in the count)1
  1. [Takayasu arteritis with pulmonary artery involvement initially presenting as community-acquired pneumonia].2023Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Earlier papers (2016–2020)3
  1. Clinical and imaging manifestations of Takayasu's arteritis with pulmonary hypertension: A retrospective cohort study in China.2019International journal of cardiology
  2. [Pulmonary cavities with Takayasu arteritis: report of 3 cases and literature review].2018Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  3. [The analysis of the clinical records diagnosed as Takayasu's arteritis with pulmonary vascular involvement].2016Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
All its trials on ClinicalTrials.gov, any status1
  1. Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's ArteritisCompletedNCT03096275Study sitePhase 3Start 2017-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 12 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.2%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 7720232024: 2220242025: 112025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led12
  1. Immunological Features and Potential Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis.2025The clinical respiratory journal
  2. Identifying prothrombin and bone sialoprotein as potential drug targets for idiopathic pulmonary fibrosis.2024BMC pulmonary medicine
  3. Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases.2024BMJ open respiratory research
  4. Mendelian randomization analysis suggests no causal influence of gastroesophageal reflux disease on the susceptibility and prognosis of idiopathic pulmonary fibrosis.2023BMC pulmonary medicine
  5. Cluster features in fibrosing interstitial lung disease and associations with prognosis.2023BMC pulmonary medicine
  6. Serum Rcn3 level is a potential diagnostic biomarker for connective tissue disease-associated interstitial lung disease and reflects the severity of pulmonary function.2023BMC pulmonary medicine
  7. MMP19 Variants in Familial and Sporadic Idiopathic Pulmonary Fibrosis.2023Lung
  8. Characteristics of Chest HRCT and pulmonary function tests in elderly-onset primary Sjögren syndrome with interstitial lung disease.2023Medicine
  9. TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation.2023Respiratory research
  10. Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis.2023Thoracic cancer
  11. Air pollution and hospitalization of patients with idiopathic pulmonary fibrosis in Beijing: a time-series study.2022Respiratory research
  12. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.2021BMC pulmonary medicine
Chinese-language papers (not in the count)1
  1. [Research progress of occupational and environmental exposure and idiopathic pulmonary fibrosis].2022Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
Earlier papers (2016–2020)21
  1. Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling.2020BMC cancer
  2. HYAL1 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits HFL-1 Fibroblast Proliferation When Upregulated.2020BioMed research international
  3. Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases.2020PloS one
  4. Mechanical ventilation for acute respiratory failure due to idiopathic pulmonary fibrosis versus connective tissue disease-associated interstitial lung disease: Effectiveness and risk factors for death.2020The clinical respiratory journal
  5. [Postinflammatroy pulmonary fibrosis of COVID-19: the current status and perspective].2020Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  6. [A concise review of telomere and telomerase-related genetic markers in fibrotic lung diseases].2020Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  7. Independent Clinical Factors Relevant to Prognosis of Patients with Idiopathic Pulmonary Fibrosis.2019Medical science monitor : international medical journal of experimental and clinical research
  8. Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis.2019The clinical respiratory journal
  9. Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone.2019Therapeutic advances in respiratory disease
  10. A Rare Missense Variant in Telomerase Reverse Transcriptase is Associated with Idiopathic Pulmonary Fibrosis in a Chinese Han Family.2018Chinese medical journal
  11. Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia.2018Clinical rheumatology
  12. Differentiating Usual Interstitial Pneumonia From Nonspecific Interstitial Pneumonia Using High-resolution Computed Tomography: The "Straight-edge Sign".2018Journal of thoracic imaging
  13. Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis.2018The clinical respiratory journal
  14. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.2018The clinical respiratory journal
  15. [Real-life experience with pirfenidone in idiopathic pulmonary fibrosis].2018Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  16. Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis.2017Respiratory research
  17. Fibrinolytic system related to pulmonary arterial pressure and lung function of patients with idiopathic pulmonary fibrosis.2017The clinical respiratory journal
  18. [Clinical features of acute diffuse pulmonary exudative disorders].2017Zhonghua yi xue za zhi
  19. [Differentially expressed genes analysis in expression profile data of pulmonary fibrosis with pulmonary hypertension].2017Zhonghua yi xue za zhi
  20. Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis via multiple pathways.2016Experimental biology and medicine (Maywood, N.J.)
  21. miR-130b-3p Modulates Epithelial-Mesenchymal Crosstalk in Lung Fibrosis by Targeting IGF-1.2016PloS one
All its trials on ClinicalTrials.gov, any status8
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  4. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  5. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  6. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Study sitePhase 3Start 2020-09
  7. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06
  8. Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01170065Study sitePhase 2Start 2010-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 3 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 2 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 2.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

10 hospitals in Beijing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Beijing for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Beijing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Chinese-language papers (not in the count)1
  1. [Current management status of hereditary colorectal cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

首都医科大学附属北京朝阳医院

Beijing Chao-Yang Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Beijing Chaoyang Hospital; Beijing Chao-yang Hospital; Beijing Chaoyang Hospital Affiliated to Capital Medical University; Myeloma Research Center of Beijing Beijing Chao-Yang Hospital; Beijing Chao-yang Hospital Affiliated with Capital Medical University; Beijing Chao-yang Hospital Affiliated to Capital Medical University; Beijing Chaoyang Hospital Capital Medical University; Capital Medical University Beijing Chaoyang Hospital

Suggest a correctionDownload the data